Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate atomoxetine's efficacy in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and atomoxetine's effect on functional outcomes in young adults.

A gatekeeper strategy will be employed for sequentially testing the secondary objectives.

This study also has an observational community sample arm in which patients will complete all the efficacy measurements via web-based self reporting.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Atomoxetine Hydrochloride

Criteria

Inclusion Criteria:

• positive attention-deficit/hyperactivity disorder (ADHD) diagnosis with at least moderate severity

• male or female 18 to 30 years of age

• must be able to swallow capsules

• must be able to communicate effectively in English

• must not have cognitive impairment

• be reliable to keep appointments for clinic visits and all related tests

Exclusion Criteria:

• patients diagnosed with obsessive-compulsive disorder, bipolar affective disorder, or psychosis

• females who are pregnant or breastfeeding

• patients with dementia or traumatic brain injury

• patients with a history of severe allergy to atomoxetine

• have untreated hypertension or thyroid problem

• have serious medical illness including any heart, liver, kidney, respiratory, blood, endocrine, or neuromuscular diseases